[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-for-example-fluid-overload\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-for-example-fluid-overload":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100631299","detecting-the-undetected-heart-failure-screening-at-the-lymphoedema-point-of-care-100631299",false,"NCT07498868","Detecting the Undetected: Heart Failure Screening at the Lymphoedema Point of Care","Detecting the Undetected: an Observational Cohort Study Evaluating the Health Economics, Clinical Utility, and Patient and Staff Experiences of Innovative Peptide Testing to Screen for Heart Failure in Lymphoedema Clinics","Inclusion Criteria:\n\n* Patient of Swansea Bay University Health Board Lymphoedema Service.\n* Consent to participate in the study.\n* Bilateral lower limb oedema.\n* Aged 18-years or older.\n* Able to provided informed consent to be involved.\n* No diagnosis of heart failure.\n* No NT-proBNP test in the previous 12-months OR increase in lymphoedema severity since an NT-proBNP test in the last 12-months.\n\nExclusion Criteria:\n\n* All inclusion criteria not met.\n* Not a lymphoedema patient in Swansea Bay University Health Board Lymphoedema Service.\n* Unable to consent for themselves.\n* Women who are pregnant or have given birth in the last 6-months.\n* Patients with an existing heart failure diagnosis.","ALL","18 Years",{"count":19,"type":20},618,"ESTIMATED","OBSERVATIONAL","Heart failure affects more people than the four most common cancers combined. When identified early, management is more straightforward, preventing complications, hospitalisations, and fatalities. Breathlessness and fatigue are cardinal symptoms of heart failure that can present in a number of conditions. As a result, leg swelling, the third cardinal symptom, is the first noted in many people. The presence of leg swelling leads to patients being seen in lymphoedema clinics before the need for cardiology investigation has been identified. Lymphoedema is the presence of chronic oedema as a result of congenital abnormalities, inflammation, infection, trauma, or cancer and its treatments. The vast majority of lymphoedema patients have swelling in their legs.\n\nA recent study has shown that 9.4% lymphoedema patients need to be investigated for heart failure. At present, the need for investigation is identified by performing a laboratory blood test, which takes time to arrange and complete. An alternate point of care test can provide a result in 12-minutes at the lymphoedema appointment, and enable appropriate action to be taken. This can reduce the demands on primary care and shorten the chain of events to a specialist assessment, as well as reducing inappropriate referrals.\n\nThis research, funded by NHS Wales Performance and Improvement, will perform a point of care test to screen for possible heart failure in lymphoedema clinics and establish the clinical utility by exploring the experiences of patients and staff involved and determining the health economic benefits. A supplementary aim is to compare the point of care test to the currently used laboratory test in a subsample to promote confidence in the test and support efforts to spread and scale across all health boards in Wales on completion.",[24,25,26,27,28],"Lymphedema, Lower Limb","Lymphedema","Heart Failure","Heart Failure (for Example, Fluid Overload)","Heart Failure (HF)",[30,31,32,33,34,35,36,37,38],"lymphoedema","heart failure","undetected heart failure","undiagnosed heart failure","bilateral lower limb oedema","bilateral leg oedema","point of care testing","screening","NT-proBNP","NOT_YET_RECRUITING","2026-03-23",{"date":42,"type":43},"2026-03-27","ACTUAL",{"date":45,"type":20},"2026-05",{"date":47,"type":20},"2028-09",{"name":49,"class":50},"Swansea Bay University Health Board","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100630156","reds-guided-decongestion-strategy-in-patients-hospitalized-for-heart-failure-100630156","NCT07484009","ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure","ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure: the ReDS-SAFE HF II Trial","ReDS-SAFE HF 2","Inclusion Criteria:\n\n1. Hospitalized due to heart failure as the main reason, including the presence of symptoms and signs of congestion, regardless of the left ventricular ejection fraction (LVEF).\n2. NT-proBNP greater than 1000 pg\u002FL or BNP greater than 300 pg\u002FL upon admission.\n\nExclusion Criteria:\n\n1. Height less than 150 cm or greater than 190 cm or body mass index (BMI) less than 22 or greater than 39, conditions where the use of ReDS is not approved.\n2. Patients requiring inotropes (levosimendan is allowed) or vasopressors upon admission, with mechanical support, or heart transplant recipients.\n3. Any malformation or variant affecting the right lung anatomy (e.g., a pacemaker).\n4. Patients with any heart disease requiring a planned surgical intervention (CABG, valve disease, or other) or percutaneous (TAVR, STE-ACS, mitral or tricuspid valve repair, CRT) during the clinical trial.\n5. Chronic kidney disease with a GFR \\\u003C20 or on hemodialysis.\n6. Life expectancy less than 12 months due to non-cardiological origin.\n7. Participation in another clinical trial with intervention.",{"count":61,"type":20},1014,"INTERVENTIONAL",[64],"NA","This clinical trial aims to determine whether a ReDS-guided treatment strategy is superior to the current standard of care for adults hospitalized with heart failure. Additionally, the study will evaluate the safety and cost-effectiveness of this approach.\n\nThe study seeks to answer the following key questions:\n\n1. Does the ReDS-guided strategy reduce the risk of cardiovascular events during the first month following hospital discharge?\n2. What is the safety profile of this treatment strategy?\n\nResearchers will compare the ReDS-based strategy against the current standard of care. All participants will:\n\n* Undergo daily assessments using the ReDS device throughout their hospitalization.\n* Attend two follow-up visits post-discharge, scheduled at 2 weeks and 30 days.",[67,27,68],"Acute Heart Failure (AHF)","Heart Failure Hospitalization",[70,71,72,73,74],"Heart failure","Congestion","ReDS","Fluid Overload","Randomized Clinical Trial","RECRUITING","2026-03-16",{"date":78,"type":43},"2026-03-19",{"date":80,"type":43},"2026-01-29",{"date":82,"type":20},"2027-08-31",{"name":84,"class":50},"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal",25,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":96,"studyType":21,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":51},"100605097","molecular-underpinnings-of-heart-failure-integrative-multi-omics-and-non-coding-rna-profiling-100605097","NCT07158086","Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling","Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling: the BIOCARDIUM-HF Study","BIOCARDIUM-HF","INCLUSION CRITERIA\n\n* Female and Male, age ≥18 years at screening.\n* Diagnosis of Heart Failure according to ESC Heart Failure Guidelines\n* Ability to understand the requirements of the study and to provide informed consent.\n* Willingness to undergo follow-up.\n\nEXCLUSION CRITERIA\n\nPatients will be excluded if they meet any of the following conditions:\n\n* Active malignancy or history of cancer with ongoing treatment (e.g., chemotherapy, radiotherapy, immunotherapy).\n* Autoimmune or systemic inflammatory diseases.\n* Concomitant infections, including acute systemic infections (e.g., sepsis, pneumonia) or chronic infections with systemic impact (e.g., HIV, hepatitis B\u002FC with elevated transaminases).\n\nOther exclusion criteria:\n\n* Age\\\u003C18 years old\n* Inability to provide written informed consent",{"count":95,"type":20},500,"5 Years","The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients.\n\nThe secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.",[26,27],"2025-09-09",{"date":101,"type":43},"2025-09-10",{"date":103,"type":20},"2025-11-01",{"date":105,"type":20},"2031-11-30",{"name":107,"class":50},"University of Zurich"]